Mary Riwes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mary Riwes has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Pavan Reddy
Baylor College of Medicine
4 shared publications - Attaphol Pawarode
Rogel Cancer Center, and
2 shared publications John Magenau
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, USA
2 shared publications- Sung Won Choi
Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA
2 shared publications - Thomas M. Braun
University of Michigan School of Public Health, Ann Arbor, MI
2 shared publications - Amanda Mazzoli
William Beaumont School of Medicine, Oakland University, Rochester, MI, USA
1 shared publication
Latest Publications
- Open Access
- 19 October 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (11) , 2805-2813
Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation
Evaluation of the impact of dietary intervention on gastrointestinal microbiota and metabolites after allogeneic hematopoietic stem cell transplantation (HCT) is lacking. We conducted a feasibility study as the first of a two-phase trial. Ten adults received resistant potato starch (RPS) daily from day −7 to day 100. The primary objective was to test the feasibility of RPS and its effect on intestinal microbiome and metabolites, including the short-chain fatty acid butyrate. Feasibility met the preset goal of 60% or more, adhering to 70% or more doses; fecal butyrate levels were significantly higher when participants were on RPS than when they were not (P < 0.0001). An exploratory objective was to evaluate plasma metabolites. We observed longitudinal changes in plasma metabolites compared to baseline, which were independent of RPS (P < 0.0001). However, in recipients of RPS, the dominant plasma metabolites were more stable compared to historical controls with significant difference at engraftment (P < 0.05). These results indicate that RPS in recipients of allogeneic HCT is feasible; in this study, it was associated with significant alterations in intestinal and plasma metabolites. A phase 2 trial examining the effect of RPS on graft-versus-host disease in recipients of allogeneic HCT is underway. ClinicalTrials.gov registration: NCT02763033.
- 19 October 2023
- Published by Springer Nature in Nature Medicine
- Vol. 29 (11) , 2805-2813
Open AccessFeasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation
Evaluation of the impact of dietary intervention on gastrointestinal microbiota and metabolites after allogeneic hematopoietic stem cell transplantation (HCT) is lacking. We conducted a feasibility study as the first of a two-phase trial. Ten adults received resistant potato starch (RPS) daily from day −7 to day 100. The primary objective was to test the feasibility of RPS and its effect on intestinal microbiome and metabolites, including the short-chain fatty acid butyrate. Feasibility met the preset goal of 60% or more, adhering to 70% or more doses; fecal butyrate levels were significantly higher when participants were on RPS than when they were not (P < 0.0001). An exploratory objective was to evaluate plasma metabolites. We observed longitudinal changes in plasma metabolites compared to baseline, which were independent of RPS (P < 0.0001). However, in recipients of RPS, the dominant plasma metabolites were more stable compared to historical controls with significant difference at engraftment (P < 0.05). These results indicate that RPS in recipients of allogeneic HCT is feasible; in this study, it was associated with significant alterations in intestinal and plasma metabolites. A phase 2 trial examining the effect of RPS on graft-versus-host disease in recipients of allogeneic HCT is underway. ClinicalTrials.gov registration: NCT02763033.
- 11 June 2020
- Published by Elsevier in Seminars in Hematology
- Vol. 57 (1) , 1-6
Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis
- 11 June 2020
- Published by Elsevier in Seminars in Hematology
- Vol. 57 (1) , 1-6
Short chain fatty acids: Postbiotics/metabolites and graft versus host disease colitis
- Open Access
- 1 August 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (8) , 1492-1497
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- 1 August 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (8) , 1492-1497
Open AccessA Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
- Open Access
- 1 August 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (8) , 1682-1688
Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation
- 1 August 2019
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 25 (8) , 1682-1688
Open AccessAssessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation
- Open Access
- 1 December 2012
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 5 (6) , 661-669
Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies
Invasive fungal disease is associated with increased morbidity and mortality in hematologic malignancy patients and hematopoietic stem cell transplant recipients. Timely recognition and treatment o...
- 1 December 2012
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 5 (6) , 661-669
Open AccessDiagnostic methods for invasive fungal diseases in patients with hematologic malignancies
Invasive fungal disease is associated with increased morbidity and mortality in hematologic malignancy patients and hematopoietic stem cell transplant recipients. Timely recognition and treatment o...